HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease.

AbstractBACKGROUND:
Intralesional therapies provide an alternative to surgical treatment of Peyronie's disease (PD). This study examines the efficacy of intraplaque injections of interferon-alpha-2B (IFN-alpha-2B) in the treatment of PD.
METHODS:
Twenty-five patients were enrolled in the study with 21 completing the study. The average age of the study participants was 55.8 years, with 10 of the 21 having diabetes, hypertension, or both. Seven patients received placebo injections using 10 ml saline biweekly for 6 weeks before interferon therapy, and all 21 patients received biweekly injections of 2 x 10(6) U IFN-alpha-2B for 6 weeks before reevaluation. Patients were evaluated with duplex Doppler ultrasonography to assess penile curvature and blood flow.
RESULTS:
The International Index of Erectile Function questionnaire was completed by 14 of 21 men to assess severity of erectile dysfunction (ED) before and after treatment. Improvements of 20% or more in penile curvature occurred in 14 (67%) of 21 men. Penile pain decreased in eight (80%) of 10, and plaque size decreased subjectively in 15 (71%) of 21 participants. The International Index of Erectile Function questionnaire showed significant improvement of ED in five (71%) of seven men with baseline moderate to severe ED. Peak systolic blood flow improved in three (43%) of seven men with baseline hemodynamic impairment, and veno-occlusive disease resolved in three (18%) of 17 individuals. IFN-alpha-2B injections led to significant improvements in penile pain and curvature caused by PD.
CONCLUSION:
Results of intralesional IFN-alpha-2B injections in improving ED are encouraging. The study findings warrant further investigation of the effectiveness of IFN-alpha-2B injections for treatment of PD.
AuthorsGerald Dang, Richard Matern, Trinity J Bivalacqua, Suresh Sikka, Wayne J G Hellstrom
JournalSouthern medical journal (South Med J) Vol. 97 Issue 1 Pg. 42-6 (Jan 2004) ISSN: 0038-4348 [Print] United States
PMID14746421 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
Topics
  • Adult
  • Aged
  • Angiogenesis Inhibitors (therapeutic use)
  • Blood Flow Velocity
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Impotence, Vasculogenic (drug therapy, etiology)
  • Injections, Intralesional
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Male
  • Middle Aged
  • Pain (drug therapy, etiology)
  • Penile Induration (complications, diagnostic imaging, drug therapy)
  • Penis (blood supply, diagnostic imaging)
  • Recombinant Proteins
  • Regional Blood Flow
  • Surveys and Questionnaires
  • Treatment Outcome
  • Ultrasonography, Doppler, Duplex

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: